Initially, monotherapy with antiangiogenic agents, such as the anti-VEGF antibody bevacizumab, by blocking the VEGF/VEGFR-dependent survival and growth of the blood vasculature, was thought to starve the tumor thus halting tumor progression and improving patient survival. This evidence concerns the gene VEGFA and neoplasm.